NO20051074L - Forbindelser som kan anvendes til behandlingen av sykdommer som gir respons pa antiangiogenetisk terapi - Google Patents

Forbindelser som kan anvendes til behandlingen av sykdommer som gir respons pa antiangiogenetisk terapi

Info

Publication number
NO20051074L
NO20051074L NO20051074A NO20051074A NO20051074L NO 20051074 L NO20051074 L NO 20051074L NO 20051074 A NO20051074 A NO 20051074A NO 20051074 A NO20051074 A NO 20051074A NO 20051074 L NO20051074 L NO 20051074L
Authority
NO
Norway
Prior art keywords
treatment
diseases
compounds
respond
antiangiogenetic
Prior art date
Application number
NO20051074A
Other languages
English (en)
Inventor
Palle Christophersen
Bjarne H Dahl
Jens Lichtenberg
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of NO20051074L publication Critical patent/NO20051074L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Denne oppfinnelsen vedrører anvendelsen av bestemte forbindelser til behandling av sykdommer som gir respons på antiangiogenetisk terapi. For mye angiogenese inntrer ved slike sykdommer som kreft, diabetisk blindhet, aldersrelatert makuløs degenerasjon, revmatoid artritt og psoriasis. Forbindelsene er særlig anvendbare til anti-metastatisk behandling eller til behandling av aldersrelatert makuløs degenerasjon.
NO20051074A 2002-08-01 2005-02-28 Forbindelser som kan anvendes til behandlingen av sykdommer som gir respons pa antiangiogenetisk terapi NO20051074L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200201165 2002-08-01
DKPA200201839 2002-11-28
DKPA200300371 2003-03-11
PCT/DK2003/000518 WO2004012733A2 (en) 2002-08-01 2003-07-31 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy

Publications (1)

Publication Number Publication Date
NO20051074L true NO20051074L (no) 2005-04-29

Family

ID=31498946

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051074A NO20051074L (no) 2002-08-01 2005-02-28 Forbindelser som kan anvendes til behandlingen av sykdommer som gir respons pa antiangiogenetisk terapi

Country Status (17)

Country Link
US (1) US20060058395A1 (no)
EP (1) EP1526851B1 (no)
JP (1) JP2005537336A (no)
KR (1) KR20050026091A (no)
CN (1) CN1671378A (no)
AT (1) ATE372770T1 (no)
AU (1) AU2003260280A1 (no)
BR (1) BR0312929A (no)
CA (1) CA2493253A1 (no)
DE (1) DE60316297T2 (no)
IL (1) IL166040A0 (no)
IS (1) IS7723A (no)
MX (1) MXPA05001235A (no)
NO (1) NO20051074L (no)
NZ (1) NZ537809A (no)
PL (1) PL375318A1 (no)
WO (1) WO2004012733A2 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1805942B (zh) * 2003-06-17 2010-06-02 神经研究公司 二苯基脲衍生物及其作为氯离子通道阻断剂的用途
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
EP1853286A2 (en) * 2005-02-08 2007-11-14 BMZ Diagnosis (2004) Ltd. Composition for treatment of skin disorders
AR056867A1 (es) 2005-06-27 2007-10-31 Bristol Myers Squibb Co Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
ATE485269T1 (de) 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
WO2007002584A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2009054878A2 (en) * 2007-09-11 2009-04-30 University Of Florida Research Foundation Compositions and methods for the treatment of neoplasia
WO2016001452A1 (en) * 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
ES2770374T3 (es) * 2016-05-17 2020-07-01 Scandion Oncology As Tratamiento combinado de cáncer
WO2020049139A1 (en) * 2018-09-06 2020-03-12 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
TR199902593T2 (xx) * 1997-04-22 2000-03-21 Neurosearch A/S �kame edilmi� fenil t�revleri, bunlar�n haz�rlanmas� ve kullan�m�.
ATE291011T1 (de) * 1997-12-22 2005-04-15 Bayer Pharmaceuticals Corp Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
EP1514867A3 (en) * 1998-10-22 2005-03-23 NeuroSearch A/S Substituted phenyl derivatives, their preparation and use
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
US6875782B2 (en) * 2002-07-09 2005-04-05 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Also Published As

Publication number Publication date
WO2004012733A9 (en) 2005-03-10
IS7723A (is) 2005-03-01
IL166040A0 (en) 2006-01-15
EP1526851B1 (en) 2007-09-12
JP2005537336A (ja) 2005-12-08
DE60316297D1 (de) 2007-10-25
AU2003260280A1 (en) 2004-02-23
WO2004012733A3 (en) 2004-03-18
MXPA05001235A (es) 2005-06-08
ATE372770T1 (de) 2007-09-15
US20060058395A1 (en) 2006-03-16
EP1526851A2 (en) 2005-05-04
BR0312929A (pt) 2005-07-12
DE60316297T2 (de) 2008-06-19
NZ537809A (en) 2007-05-31
KR20050026091A (ko) 2005-03-14
WO2004012733A2 (en) 2004-02-12
PL375318A1 (en) 2005-11-28
CN1671378A (zh) 2005-09-21
CA2493253A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
JOP20220083A1 (ar) حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
TW200736231A (en) Substituted pyrimidines
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
EA202091708A1 (ru) Ингибиторы днк-пк
NO20062876L (no) Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater
WO2004032882A3 (en) Chemical compounds
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
MX2022004989A (es) Composiciones farmaceuticas de albumina y rapamicina.
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
EP4183806A3 (en) Glycan-interacting compounds and methods of use
AU2003220970A1 (en) Diamino-pyrimidines and their use as angiogenesis inhibitors
AU2017206631A8 (en) Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
NO20084396L (no) Kombinasjonsterapi
EP1503757A4 (en) Tyrosine kinase inhibitor
EA200970280A1 (ru) Ингибиторы киназ, полезные для лечения пролиферативных заболеваний
ATE553122T1 (de) Antiangiogene methoden und zusammensetzungen
WO2006121610A3 (en) Personal care compositions and methods for their use
WO2004071448A3 (en) Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
MX388660B (es) DERIVADOS DE N-(SUSTITUIDA-FENIL)-SULFONAMIDA COMO INHIBIDORES DE QUINASA N-(sustituida-fenil)-sulfonamida.
WO2004060890A8 (en) 2-oxopyridin-3-yl thia (di) azole derivates for use in the treatment of cell proliferation and apoptosis related diseases
IS7723A (is) Efnasambönd sem eru gagnleg til meðhöndlunar á sjúkdómum sem svara meðferð sem bælir æðamyndun
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
AU2017329645A8 (en) Novel antibodies against Factor XI and uses thereof